Chromadex Corp (NASDAQ:CDXC) dropped 0% during trading on Friday . The company traded as low as $4.33 and last traded at $4.83. Approximately 1,012,374 shares changed hands during trading, an increase of 91% from the average daily volume of 529,140 shares. The stock had previously closed at $4.83.
CDXC has been the subject of a number of recent research reports. HC Wainwright set a $8.00 price objective on Chromadex and gave the company a “buy” rating in a research report on Tuesday, January 16th. ValuEngine downgraded Chromadex from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub downgraded Chromadex from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 22nd. Finally, Zacks Investment Research raised shares of Chromadex from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a research note on Tuesday, November 28th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $7.50.
The company has a current ratio of 5.03, a quick ratio of 4.12 and a debt-to-equity ratio of 0.01.
In other news, CEO Frank L. Jaksch, Jr. sold 28,379 shares of the company’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $6.52, for a total value of $185,031.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Frank L. Jaksch, Jr. sold 58,400 shares of the company’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $6.19, for a total transaction of $361,496.00. The disclosure for this sale can be found here. 11.59% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Deutsche Bank AG increased its stake in shares of Chromadex by 31,769.4% in the fourth quarter. Deutsche Bank AG now owns 22,946 shares of the company’s stock worth $134,000 after acquiring an additional 22,874 shares during the last quarter. Monashee Investment Management LLC acquired a new position in shares of Chromadex in the fourth quarter worth $140,000. Two Sigma Investments LP acquired a new position in shares of Chromadex in the fourth quarter worth $145,000. Cetera Advisor Networks LLC acquired a new position in shares of Chromadex in the fourth quarter worth $147,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Chromadex in the fourth quarter worth $250,000. 10.30% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2018/03/11/chromadex-cdxc-stock-price-down-0.html.
Chromadex Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.